Plasma adiponectin concentrations and risk of incident breast cancer.

Plasma adiponectin concentrations and risk of incident breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Plasma adiponectin concentrations and risk of incident breast cancer. Abstract Text:

Shelley S Tworoger,A Heather Eliassen,Theodoros Kelesidis,Graham A Colditz,Walter C Willett,Christos S Mantzoros,Susan E Hankinson,

INTRODUCTION: Previous retrospective case-control studies suggest that adiponectin, an obesity-related hormone, is inversely associated with breast cancer risk, particularly in postmenopausal women; however, no prospective studies exist. Therefore, we conducted a prospective case-control study nested within the Nurses' Health Study (NHS) and NHSII cohorts examining the association between plasma adiponectin concentrations and breast cancer risk. MATERIALS AND METHODS: Blood samples were collected from 1989 through 1990 (NHS) and 1996 through 1999 (NHSII); adiponectin was measured by RIA. The analysis included 1477 breast cancer cases diagnosed after blood collection and before June 2000 (NHS) or June 2003 (NHSII) who had one or two controls (n=2196) matched on age, menopausal status, postmenopausal hormone (PMH) use, fasting, and time of day and month of blood collection. We adjusted for body mass index at age 18, weight change from age 18 to blood draw, family history of breast cancer, history of benign breast disease, duration of PMH use, ages at menarche and first birth, and parity. RESULTS: Although we observed no association between adiponectin and breast cancer risk overall, there was a nearly significant interaction by menopausal status (P=0.08), with a relative risk, top vs. bottom quartile of 0.73 (95% confidence interval, 0.55-0.98; P trend=0.08) among postmenopausal women and 1.30 (95% confidence interval, 0.80-2.10; P trend=0.09) for premenopausal women. Among postmenopausal women, adiponectin appeared more strongly inversely associated in women who never used PMH (P heterogeneity=0.05) and women with low circulating estradiol levels (P heterogeneity=0.05). DISCUSSION: Our results suggest that adiponectin may be inversely associated with postmenopausal breast cancer risk, particularly in a low-estrogen environment.

Plasma adiponectin concentrations and risk of incident breast cancer. Publishing Authors By Initials

SS Tworoger,AH Eliassen,T Kelesidis,GA Colditz,WC Willett,CS Mantzoros,SE Hankinson,

For similar diagnosis: diagnostic techniques and procedures: diagnostic techniques, radioisotope: radioimmunoassay research abstracts see: diagnosis: diagnostic techniques and procedures: diagnostic techniques, radioisotope: radioimmunoassay research

PUBMED ID PMID:

MEDLINE DATE:

Plasma adiponectin concentrations and risk of incident breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The Journal of clinical endocrinology and metaboli

VOLUME: 92

Page Numbers: 1510-6

Journal Abbreviation:

ISSN: 0021-972X

DAY: 9

MONTH: 01

YEAR: 2007

Plasma adiponectin concentrations and risk of incident breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 375362

Plasma adiponectin concentrations and risk of incident breast cancer. Keywords Mesh Terms:

KEYWORDS: Radioimmunoassay

MESH TERMS: epidemiology

Chemical & Substance for Abstract: Plasma adiponectin concentrations and risk of incident breast cancer. Information

Substance Name: Adiponectin

Registry Number: 0

Grant and Affiliation Information for Plasma adiponectin concentrations and risk of incident breast cancer.

AFFILIATION: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Third Floor, Boston, Massachusetts 02115, USA. nhsst@channing.harvard.edu

Country: United States

AGENCY: United States NCI

GRANT: R25 CA 098566-2

ACRONYM: CA

MEDLINETA: J Clin Endocrinol Metab

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Plasma adiponectin concentrations and risk of incident breast cancer Related Publications

• A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia.
• A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer.
• A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
• A prospective study of postmenopausal hormone use and ovarian cancer risk.
• Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer.
• Association of activity and chronic disease risk factors: utility and limitations of objectively measured physical activity data.
• Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.
• Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women.
• Body shape throughout life and correlations with IGFs and GH.
• Breastfeeding and risk of ovarian cancer in two prospective cohorts.
• Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
• Circulating colony stimulating factor-1 and breast cancer risk.
• Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women.
• Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
• Dietary patterns, the Alternate Healthy Eating Index and plasma sex hormone concentrations in postmenopausal women.
• Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.
• Identification of novel dioxin-responsive genes by representational difference analysis.
• Identifying target genes of the aryl hydrocarbon receptor nuclear translocator (Arnt) using DNA microarray analysis.
• Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts.
• Menopausal and reproductive factors and risk of age-related macular degeneration.
• Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - exercise and premenopausal hormones.
• Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer.
• Plasma adiponectin concentrations and risk of incident breast cancer.
• Plasma androgen concentrations and risk of incident ovarian cancer.
• Prolactin and breast cancer risk.
• Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels.
• Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.
• The role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon receptor action.
• Use of biomarkers in epidemiologic studies: minimizing the influence of measurement error in the study design and analysis.
• Why does ARNT2 behave differently from ARNT?